Thu. 11 Apr 2024, 7:02am ET
Benzinga
Biotech, Large Cap, News, Health Care, FDA, General
FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1